Advancements in Novel Live Biotherapeutic Products for Clostridioides difficile Infection Prevention.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic methodology or primary human data.
PubMed 38051964 · doi:10.1093/cid/ciad639
What was done
This narrative review synthesized the role of gut microbiome dysbiosis in Clostridioides difficile infection (CDI) pathogenesis and evaluated microbiota-restoring interventions, including fecal microbiota transplantation (FMT) and two FDA-approved live biotherapeutic products (Fecal Microbiota Live-JSLM and Fecal Microbiota Spores Live-BRPK).
What was found
The abstract provides no numerical data, sample sizes, or statistical metrics. It qualitatively reports that standard antibiotic regimens (vancomycin, fidaxomicin) fail to resolve dysbiosis, whereas FMT and live biotherapeutic products increase bacterial diversity and show efficacy in preventing CDI recurrence.
Why it matters
It outlines a therapeutic paradigm shift for recurrent CDI from repeated antimicrobial suppression to targeted ecological restoration of the gut microbiota.
Limits
This is a narrative review with no systematic search methodology, meta-analytic pooling, or new empirical data. The abstract lacks quantitative efficacy and safety comparisons among the discussed products.
Cited by
- contradicts No probiotic preparation has been approved as a medical drug intervention by the FDA or the European Medicines Agency.